Schwartz EJ et al. (2005) Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16: 2412–2420
The epidemic of HIV-associated end-stage renal disease (HIV + ESRD) is projected to worsen over the next 15 years despite the use of highly active antiretroviral therapy (HAART), according to a retrospective analysis of epidemiologic data from the US. Previous claims that the problem is under control might be dangerously misleading.
As most sufferers of HIV-associated nephropathy are black, a predictive model was developed using data from black AIDS and ESRD populations. Inclusion of data from 4 years before to 7 years after the introduction of HAART, together with infection rate, permitted assessment of the effect of HAART on the prevalence of HIV + ESRD to date. The validated model was then used to estimate prevalence through to 2020.
HAART was seen to have had a positive impact on AIDS growth rate since its introduction in 1995. It has also slowed progression to ESRD by at least 38% and reduced ESRD-associated mortality by 67%. Unfortunately, the model predicts that current linear rates of HIV infection will negate these positive effects, causing the HIV + ESRD population to grow steadily over the next 15 years. This increase will manifest even if the efficacy of HAART in blocking progression to ESRD reaches 95% or ESRD-associated mortality decreases to 10%.
The authors conclude that the HIV + ESRD epidemic is far from reaching a plateau. They recommend more widespread implementation of HAART and an emphasis on preventing new infections.
Rights and permissions
About this article
Cite this article
Williams, R. Impact of HAART on the ESRD epidemic is confounded by HIV infection rates. Nat Rev Nephrol 1, 4 (2005). https://doi.org/10.1038/ncpneph0002
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0002